Basic Information
| Drug ID | DDPD01200 |
|
| Drug Name | Bromocriptine | |
| Molecular Weight | 654.595 | |
| Molecular Formula | C32H40BrN5O5 | |
| CAS Number | 25614-03-3 | |
| SMILES | [H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C | |
| External Links | ||
| DRUGBANK | DB01200 | |
| T3DB | T3D3017 | |
| PubChem Compound | 31101 | |
| PDR | 1309 | |
| Drugs.com | Drugs.com Drug Page | |
Experimental Physicochemical Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Reference |
|---|---|---|---|---|---|
| Log P | 3.5 | - | 3.5 | - | DRUGBANK |
| Melting Point | 216.5 | ℃ | 215-218 | ℃ | Fluckiger, E.,Troxler, F. and Hofmann, A,; US. Patent 3,752,814; August 14, 1973; assigned to Sandoz Ltd., Switzerland. Fluckiger, E., Troxler, F. and Hofmann, A.; U.S. Patent 3,752,888; August 14, 1973; assigned to Sandoz Ltd., Switzerland. |
Pharmacokinetic/ Toxicokinetic Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Reference |
|---|---|---|---|---|---|---|
| Absorption | 28.0 | % | 28 | % | PO, oral; | DRUGBANK |
| Bioavailability | 6.0 | % | 6 | % | PO, oral; | DRUGBANK |
| T Max | 1.3 | h | 1-1.5 | h | PO, oral; | DRUGBANK |
| Metabolic | 100.0 | % | 100 | % | Liver metabolism; | DRUGBANK |
| Half-life | 5.0 | h | 2-8 | h | DRUGBANK | |
| Eliminate Route | 6.0 | % | 6 | % | Urinary excretion; | DRUGBANK |
| Protein Binding | 93.0 | % | 90-96 | % | DRUGBANK |
Maximum Dosage
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|
| Max dose for children | 10.0 | mg/day | 10 | mg/day | PO, oral | Cycloset | bromocriptine mesylate | PDR |
| Max dose for children | 5.0 | mg/day | 5 | mg/day | PO, oral | Cycloset | bromocriptine mesylate | PDR |
| Max dose for adolescents | 15.0 | mg/day | 15 | mg/day | PO, oral | Cycloset | bromocriptine mesylate | PDR |
| Max dose for adolescents | 20.0 | mg/day | 20 | mg/day | PO, oral | Cycloset | bromocriptine mesylate | PDR |
| Max dose for adolescents | 10.0 | mg/day | 10 | mg/day | PO, oral | Cycloset | bromocriptine mesylate | PDR |
| Max dose for adolescents | 20.0 | mg/day | 20 | mg/day | PO, oral | Cycloset | bromocriptine mesylate | PDR |
| Max dose for adults | 4.8 | mg/day | 4.8 | mg/day | PO, oral | Cycloset | bromocriptine mesylate | PDR |
| Max dose for adults | 30.0 | mg/day | 30 | mg/day | PO, oral | Cycloset | bromocriptine mesylate | PDR |
| Max dose for adults | 100.0 | mg/day | 100 | mg/day | PO, oral | Cycloset | bromocriptine mesylate | PDR |
| Max dose for geriatric | 4.8 | mg/day | 4.8 | mg/day | PO, oral | Cycloset | bromocriptine mesylate | PDR |
| Max dose for geriatric | 30.0 | mg/day | 30 | mg/day | PO, oral | Cycloset | bromocriptine mesylate | PDR |
| Max dose for geriatric | 100.0 | mg/day | 100 | mg/day | PO, oral | Cycloset | bromocriptine mesylate | PDR |
Drug Property Radar Chart
Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1